Merck (known as MSD outside the United States and Canada) and BGI (formerly known as Beijing Genomics Institute) have recently announced the signing of a statement of intent to initiate and develop a working relationship in which they will explore areas of mutual interest in healthcare research and discovery.
Merck (known as MSD outside the United States and Canada) and BGI (formerly known as Beijing Genomics Institute) have recently announced the signing of a statement of intent to initiate and develop a working relationship in which they will explore areas of mutual interest in healthcare research and discovery. Their common goal will be to create value from the massive output of genomic information enabled by next-generation, high-throughput DNA sequencing and analysis technologies.
Commenting on the statement of intent, Peter S. Kim, president of Merck Research Laboratories, said, “The science and technology of genomics and epigenetics offer the potential to transform medicine. We are excited to move forward towards a collaboration with BGI in our efforts to advance these areas of research.”
Both companies intend to build the infrastructure to support collaboration in areas such as biomarkers, target validation and drug de-risking and development among others.
For more information on BGI visit www.genomics.cn and www.bgiamericas.com and for MSD, please visit www.merck.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.